市場調查報告書
商品編碼
955320

膽道閉鎖(BA):流行病學預測(2030年)

Biliary Atresia (BA) - Epidemiology Forecast - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

主要7個國家(美國、德國、西班牙、義大利、法國、英國、日本)的膽道閉鎖的總患病數,2017年613人估計。美國患病數最多,其次是英國和法國。另一方面,西班牙最少,是27人。膽道閉鎖是新生兒肝疾病,病因依然不明。最近研究的潛在致病機制,包括遺傳的易感性,免疫系的參與,病毒和毒素等環境障礙等。

本報告提供主要7個國家(美國、德國、西班牙、義大利、法國、英國、日本)的膽道閉鎖概要和流行病學預測。

目錄

第1章 主要洞察

第2章 膽道閉鎖:患者概述

  • 2017年的膽道閉鎖的患者佔有率分佈
  • 2030年的膽汁封閉症的患者佔有率分佈

第3章 摘要整理

第4章 組織

第5章 疾病概要:膽道閉鎖

  • 簡介
  • 徵兆與症狀
  • 膽道閉鎖的分類
    • 解剖學的形態
    • 膽道閉鎖臨床表現型
    • 葛西分類
  • 病因
  • 診斷
    • 鑑別診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家膽道閉鎖的總患者數
  • 美國
    • 前提條件與根據
    • 膽道閉鎖的總患病數
    • 膽道閉鎖的各類型病例
    • 膽道閉鎖的性別病例
  • 歐洲5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 目前治療慣行

第8章 潛在的需求

第9章 SWOT分析

第10章 參考文件

第11章 附錄

  • 報告調查手法

第12章 DelveInsight的服務內容

第13章 免責聲明

第14章 關於DelveInsight

目錄
Product Code: DIEI0975

DelveInsight's 'Biliary Atresia (BA)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Biliary Atresia (BA) Disease Understanding

Biliary Atresia (BA) Overview

Biliary Atresia is a neonatal liver disease characterized by progressive obstruction and fibrosis of the extrahepatic biliary tree along with fibrosis and inflammation of the liver parenchyma. The etiology and pathogenesis of BA remain unknown. Recent studies are examining potential pathogenetic mechanisms of BA, including genetic susceptibility, the involvement of the immune system, and environmental insults such as viruses and toxins. It is possible that there is not a single etiological agent but rather a large group of injurious insults that might result in a final common pathway of extrahepatic bile duct obstruction and liver fibrosis.

The symptoms of biliary atresia usually appear by the age of 2-6 weeks. They include a yellowish coloration of the skin and whites of the eyes (jaundice), abnormally pale stools, and dark urine. Infants may also have swollen (distended) stomach and/or abnormal enlargement of the liver (hepatomegaly). The pathway from clinical suspicion to establishing the diagnosis of biliary atresia in a child with jaundice is a daunting task-however, investigations available help point the correct diagnosis in a reasonable time frame.Imaging by sonography has identified several parameters which can be of help in the diagnostic workup. Comparison of sonography with imaging by nuclear medicine can bring out significant differences and also avoid inappropriate imaging. The battery of biochemical tests, available currently, enable a better understanding of the line-up of investigations in a given child with neonatal cholestasis. Untreated, biliary atresia remains a fatal condition of the newborn. Most present within 4-6 weeks of conjugated jaundice and acholic stools, and although still a challenging diagnosis to make, therein lies the opportunity of changing the course of this otherwise inexorable disease.

Biliary Atresia (BA) Epidemiology

The Biliary Atresia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Biliary Atresia epidemiology segmented as the Total Incident Cases of Biliary Atresia, Type-specific Cases of Biliary Atresia, and Gender-specific Cases of Biliary Atresia. The report includes the Incident scenario of Biliary Atresia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Biliary Atresia (BA) Epidemiology

The epidemiology segment also provides the Biliary Atresia (BA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total Incident population of Biliary Atresia in the 7MM countries was estimated to be 613 in 2017.

As per the estimates, the United States has the highest Incident population of Biliary Atresia.

  • Among the EU5 countries, UK had the highest Incident population of Biliary Atresia with 45 cases, followed by France which had Incident population of 42 in 2017. On the other hand, Spain had the lowest Incident population of 27 cases in 2017.

Scope of the Report:

  • Biliary Atresia (BA) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • Biliary Atresia (BA) Epidemiology Report and Model provide an overview of the risk factors and global trends of Biliary Atresia (BA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Biliary Atresia (BA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Biliary Atresia
  • The report provides the segmentation of the Biliary Atresia (BA) epidemiology by Incident Cases of Biliary Atresia (BA) in 7MM
  • The report provides the segmentation of the Biliary Atresia (BA) epidemiology by Type -specific and Gender-specific Incident Cases of Biliary Atresia (BA) in 7MM

Report Highlights:

  • 11-Year Forecast of Biliary Atresia (BA) epidemiology
  • 7MM Coverage
  • Total Incident Cases of Biliary Atresia (BA)
  • Incident Cases according to segmentation: Type-specific cases of Biliary Atresia (BA), Gender-specific cases of Biliary Atresia (BA)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Biliary Atresia (BA)?
  • What are the key findings pertaining to the Biliary Atresia (BA) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Biliary Atresia (BA) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Biliary Atresia?
  • What are the currently available treatments of Biliary Atresia?

Reasons to buy:

The Biliary Atresia (BA) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Biliary Atresia (BA) market
  • Quantify patient populations in the global Biliary Atresia (BA) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Biliary Atresia (BA) therapeutics in each of the markets covered
  • Understand the magnitude of Biliary Atresia (BA) population by its Incidence cases
  • Understand the magnitude of Biliary Atresia (BA) population by its Etiology-specific cases
  • The Biliary Atresia (BA) epidemiology report and model were written and develoBA by Masters and Ph.D. level epidemiologists
  • The Biliary Atresia (BA) Epidemiology Model develop by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

The Biliary Atresia Research Consortium in the USA, the European Biliary Atresia Registry in Europe, and the Japanese Biliary Atresia Registry (JBAR) have been formed to help with data collection and provide a platform for large research studies.

Table of Contents

1. Key Insights

2. Biliary Atresia: Patient Overview at a Glance

  • 2.1. Patient Share (%) Distribution of Biliary Atresia in 2017
  • 2.2. Patient Share (%) Distribution of Biliary Atresia in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Biliary Atresia

  • 5.1. Introduction
  • 5.2. Signs and Symptoms
  • 5.3. Classification of Biliary Atresia
    • 5.3.1. Anatomical forms
    • 5.3.2. Clinical phenotypes of Biliary Atresia
    • 5.3.3. Kasai classification
  • 5.4. Etiology and Pathogenesis
    • 5.4.1. Pathogenesis
  • 5.5. Diagnosis
    • 5.5.1. Differential Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Incident Patient Population of Biliary Atresia
  • 6.3. United States
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Incident Cases of Biliary Atresia in the United States
    • 6.3.3. Type-specific Cases of Biliary Atresia in the United States
    • 6.3.4. Gender-specific Cases of Biliary Atresia in the United States
  • 6.4. EU-5
    • 6.4.1. Assumptions and Rationale
  • 6.5. Germany
    • 6.5.1. Total Incident Cases of Biliary Atresia in Germany
    • 6.5.2. Type-specific Cases of Biliary Atresia in Germany
    • 6.5.3. Gender-specific Cases of Biliary Atresia in Germany
  • 6.6. France
    • 6.6.1. Total Incident Cases of Biliary Atresia in France
    • 6.6.2. Type-specific Cases of Biliary Atresia in France
    • 6.6.3. Gender-specific Cases of Biliary Atresia in France
  • 6.7. Italy
    • 6.7.1. Total Incident Cases of Biliary Atresia in Italy
    • 6.7.2. Type-specific Cases of Biliary Atresia in Italy
    • 6.7.3. Gender-specific Cases of Biliary Atresia in Italy
    • 6.7.1. Total Incident Cases of Biliary Atresia in Italy
    • 6.7.2. Type-specific Cases of Biliary Atresia in Italy
    • 6.7.3. Gender-specific Cases of Biliary Atresia in Italy
  • 6.8. Spain
    • 6.8.1. Total Incident Cases of Biliary Atresia in Spain
    • 6.8.2. Type-specific Cases of Biliary Atresia in Spain
    • 6.8.3. Gender-specific Cases of Biliary Atresia in Spain
  • 6.9. UK
    • 6.9.1. Total Incident Cases of Biliary Atresia in the UK
    • 6.9.2. Type-specific Cases of Biliary Atresia in the UK
    • 6.9.3. Gender-specific Cases of Biliary Atresia in the UK

6.10.Japan

    • 6.10.1. Assumptions and Rationale
    • 6.10.2. Total Incident Cases of Biliary Atresia in Japan
    • 6.10.3. Type-specific Cases of Biliary Atresia in Japan
    • 6.10.4. Gender-specific Cases of Biliary Atresia in Japan

7. Current Treatment Practices

8. Unmet needs

9. SWOT Analysis

10. Bibliography

11. Appendix

  • 11.1 Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

List of Tables

  • Table 1: Anatomical types of biliary atresia (BA)
  • Table 2: Clinical phenotypes of Biliary Atresia
  • Table 3: Total Incident Patient Population of Biliary Atresia in 7MM (2017-2030)
  • Table 4: Total Incident cases of Biliary Atresia in the United States (2017-2030)
  • Table 5: Type-specific cases of Biliary Atresia in the United States (2017-2030)
  • Table 6: Gender-specific cases of Biliary Atresia in the United States (2017-2030)
  • Table 7: Total Incident cases of Biliary Atresia in Germany (2017-2030)
  • Table 8: Type-specific cases of Biliary Atresia in Germany (2017-2030)
  • Table 9: Gender-specific cases of Biliary Atresia in Germany (2017-2030)
  • Table 10: Total Incident cases of Biliary Atresia in France (2017-2030)
  • Table 11: Type-specific cases of Biliary Atresia in France (2017-2030)
  • Table 12: Gender-specific cases of Biliary Atresia in the France (2017-2030)
  • Table 13: Total Incident cases of Biliary Atresia in Italy (2017-2030)
  • Table 14: Type-specific cases of Biliary Atresia in Italy (2017-2030)
  • Table 15: Gender-specific cases of Biliary Atresia in Italy (2017-2030)
  • Table 16: Total Incident cases of Biliary Atresia in Spain (2017-2030)
  • Table 17: Type-specific cases of Biliary Atresia in Spain (2017-2030)
  • Table 18: Gender-specific cases of Biliary Atresia in Spain (2017-2030)
  • Table 19: Total Incident cases of Biliary Atresia in the UK (2017-2030)
  • Table 20: Type-specific cases of Biliary Atresia in the UK (2017-2030)
  • Table 21: Gender-specific cases of Biliary Atresia in the UK (2017-2030)
  • Table 22: Total Incident cases of Biliary Atresia in Japan (2017-2030)
  • Table 23: Type-specific cases of Biliary Atresia in Japan (2017-2030)
  • Table 24: Gender-specific cases of Biliary Atresia in Japan (2017-2030)

List of Figures

  • Figure 1: Signs and Symptoms
  • Figure 2: Clincal Phenotypes of BA
  • Figure 3: Classification of biliary atresia according to Kasai classification system
  • Figure 4: Schematic of the hypothesis of biliary atresia etiology
  • Figure 5: Etiology and Pathogenesis
  • Figure 6: Innate immune receptors present in Cholangiocytes
  • Figure 7: Mechanism of obstruction in biliary atresia
  • Figure 8: Disease progression mechanisms after bile duct obstruction
  • Figure 9: Total Incident Patient Population of Biliary Atresia in 7MM (2017-2030)
  • Figure 10: Total Incident cases of Biliary Atresia in the United States (2017-2030)
  • Figure 11: Type-specific cases of Biliary Atresia in the US (2017-2030)
  • Figure 12: Gender-specific cases of Biliary Atresia in the United States (2017-2030)
  • Figure 13: Total Incident cases of Biliary Atresia in Germany (2017-2030)
  • Figure 14: Type-specific cases of Biliary Atresia in the Germany 2017-2030)
  • Figure 15: Gender-specific cases of Biliary Atresia in Germany (2017-2030)
  • Figure 16: Total Incident cases of Biliary Atresia in France (2017-2030)
  • Figure 17: Type-specific cases of Biliary Atresia in the France 2017-2030)
  • Figure 18: Gender-specific cases of Biliary Atresia in France (2017-2030)
  • Figure 19: Total Incident cases of Biliary Atresia in Italy (2017-2030)
  • Figure 20: Type-specific cases of Biliary Atresia in the Italy 2017-2030)
  • Figure 21: Gender-specific cases of Biliary Atresia in Italy (2017-2030)
  • Figure 22: Total Incident cases of Biliary Atresia in Spain (2017-2030)
  • Figure 23: Type-specific cases of Biliary Atresia in the Spain 2017-2030)
  • Figure 24: Gender-specific cases of Biliary Atresia in Spain (2017-2030)